These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28193239)

  • 1. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
    Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
    J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
    Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
    Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues.
    Ma Z; Parris AB; Howard EW; Shi Y; Yang S; Jiang Y; Kong L; Yang X
    Carcinogenesis; 2018 Oct; 39(10):1264-1273. PubMed ID: 30107476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
    Zhu P; Davis M; Blackwelder AJ; Bachman N; Liu B; Edgerton S; Williams LL; Thor AD; Yang X
    Cancer Prev Res (Phila); 2014 Feb; 7(2):199-210. PubMed ID: 24322659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
    Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
    PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.
    Mezil L; Berruyer-Pouyet C; Cabaud O; Josselin E; Combes S; Brunel JM; Viens P; Collette Y; Birnbaum D; Lopez M
    PLoS One; 2012; 7(9):e43409. PubMed ID: 23028451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
    Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
    Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis.
    Xu M; Ren Z; Wang X; Comer A; Frank JA; Ke ZJ; Huang Y; Zhang Z; Shi X; Wang S; Luo J
    Mol Cancer; 2016 Jul; 15(1):52. PubMed ID: 27416801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
    Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
    BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
    Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
    Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
    Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
    Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.